Formic Acid

Formic Acid

SCHEMBL4663834

CN(C)CCn1ncc2cc(-c3cc(Nc4ccc(NS(=O)(=O)c5ccccc5F)cc4)ncn3)ccc21.O=CO

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 2/20 0.40
JAK3 P52333 2/20 0.40
JAK2 O60674 1/20 0.40
EGFR P00533 6/20 0.40
SGK1 O00141 4/20 0.36
CYP1A2 P05177 3/20 0.36
CYP2C9 P11712 3/20 0.36
CLK4 Q9HAZ1 3/20 0.36
USP2 O75604 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
CYP2C19 P33261 2/20 0.36
TSHR P16473 1/20 0.36
HSPD1 P10809 1/20 0.36
PTPN2 P17706 1/20 0.36
PTPN1 P18031 1/20 0.36
PTPN5 P54829 1/20 0.36
HSPE1 P61604 1/20 0.36
HTR6 P50406 2/20 0.36
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL4663826 0.92 JAK1 (0.42) JAK1JAK3JAK2EGFRCYP1A2
Formic Acid SCHEMBL4667433 0.92 JAK1 (0.38) JAK1JAK3JAK2EGFRSGK1
Formic Acid SCHEMBL4665793 0.86 JAK1 (0.40) JAK1JAK3JAK2EGFRPTPN2
SCHEMBL4663840 0.85 EGFR (0.40) JAK1JAK3JAK2EGFRCYP1A2
SCHEMBL4664262 0.84 HTR6 (0.53) EGFRHTR6
Formic Acid SCHEMBL4666063 0.82 NR1I2 (0.46) JAK1JAK3JAK2SGK1CYP1A2
SCHEMBL4663829 0.81 EGFR (0.39) JAK1JAK3JAK2EGFRCYP1A2
SCHEMBL4666058 0.81 BPTF (0.52) EGFRHTR6
Formic Acid SCHEMBL4664240 0.81 HTR6 (0.51) EGFRSGK1CYP1A2CYP2C9CLK4
Formic Acid SCHEMBL4663920 0.80 HTR6 (0.46) EGFRSGK1HTR6ABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 JAK1 47/4885JAK3 79/4885JAK2 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.